Ziritaxestat (GLPG1690) is a small molecule autotaxin inhibitor. It has been investigated in a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). Preclinical studies in vitro and in animal models have demonstrated its role in targeting the LPA pathway relevant to fibrotic diseases.